Patents by Inventor Tyler Jon Strang
Tyler Jon Strang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8986241Abstract: Clot disruption and dissolution are achieved using a catheter having the ability to infuse a thrombolytic agent, aspirate clot and fluid, and allow passage of a guidewire. Optionally, the catheter may also include a mechanical agitator for further disrupt clot in the presence of the thrombolytic agent. A flow resistor in the catheter provides for infusion and/or aspiration to be concentrated primarily at a clot treatment area in a blood vessel while also providing optional infusion and/or aspiration distal to the treatment area. In some embodiments, infusion, aspiration and guidewire passage occur through a common lumen. The thrombolytic agent, such as tPA, streptokinase, or urokinase, is directly released into the clot at the point where the agitator is engaging the clot. In this way, the thrombolytic activity of the agent is enhanced and the dissolution of the clot is improved.Type: GrantFiled: September 12, 2013Date of Patent: March 24, 2015Assignee: Covidien LPInventors: Michael A. Evans, Denise Zarins, Dino De Cicco, Kelvin Ning, Alexander Khairkhahan, Tyler Jon Strang
-
Publication number: 20140171911Abstract: Clot disruption and dissolution are achieved using a catheter having the ability to infuse a thrombolytic agent, aspirate clot and fluid, and allow passage of a guidewire. Optionally, the catheter may also include a mechanical agitator for further disrupt clot in the presence of the thrombolytic agent. A flow resistor in the catheter provides for infusion and/or aspiration to be concentrated primarily at a clot treatment area in a blood vessel while also providing optional infusion and/or aspiration distal to the treatment area. In some embodiments, infusion, aspiration and guidewire passage occur through a common lumen. The thrombolytic agent, such as tPA, streptokinase, or urokinase, is directly released into the clot at the point where the agitator is engaging the clot. In this way, the thrombolytic activity of the agent is enhanced and the dissolution of the clot is improved.Type: ApplicationFiled: September 12, 2013Publication date: June 19, 2014Applicant: Covidien LPInventors: Michael A. Evans, Denise Demarais, Dino De Cicco, Kelvin Ning, Alexander Khairkhahan, Tyler Jon Strang
-
Patent number: 8535290Abstract: Clot disruption and dissolution are achieved using a catheter having the ability to infuse a thrombolytic agent, aspirate clot and fluid, and allow passage of a guidewire. Optionally, the catheter may also include a mechanical agitator for further disrupt clot in the presence of the thrombolytic agent. A flow resistor in the catheter provides for infusion and/or aspiration to be concentrated primarily at a clot treatment area in a blood vessel while also providing optional infusion and/or aspiration distal to the treatment area. In some embodiments, infusion, aspiration and guidewire passage occur through a common lumen. The thrombolytic agent, such as tPA, streptokinase, or urokinase, is directly released into the clot at the point where the agitator is engaging the clot. In this way, the thrombolytic activity of the agent is enhanced and the dissolution of the clot is improved.Type: GrantFiled: July 13, 2012Date of Patent: September 17, 2013Assignee: Covidien LPInventors: Michael A. Evans, Denise Demarais, Dino De Cicco, Kelvin Ning, Alexander Khairkhahan, Tyler Jon Strang
-
Publication number: 20120283699Abstract: Clot disruption and dissolution are achieved using a catheter having the ability to infuse a thrombolytic agent, aspirate clot and fluid, and allow passage of a guidewire. Optionally, the catheter may also include a mechanical agitator for further disrupt clot in the presence of the thrombolytic agent. A flow resistor in the catheter provides for infusion and/or aspiration to be concentrated primarily at a clot treatment area in a blood vessel while also providing optional infusion and/or aspiration distal to the treatment area. In some embodiments, infusion, aspiration and guidewire passage occur through a common lumen. The thrombolytic agent, such as tPA, streptokinase, or urokinase, is directly released into the clot at the point where the agitator is engaging the clot. In this way, the thrombolytic activity of the agent is enhanced and the dissolution of the clot is improved.Type: ApplicationFiled: July 13, 2012Publication date: November 8, 2012Applicant: TYCO HEALTHCARE GROUP LPInventors: Michael A. Evans, Denise Demarais, Dino De Cicco, Kelvin Ning, Alexander Khairkhahan, Tyler Jon Strang
-
Patent number: 8241241Abstract: Clot disruption and dissolution are achieved using a catheter having the ability to infuse a thrombolytic agent, aspirate clot and fluid, and allow passage of a guidewire. Optionally, the catheter may also include a mechanical agitator for further disrupt clot in the presence of the thrombolytic agent. A flow resistor in the catheter provides for infusion and/or aspiration to be concentrated primarily at a clot treatment area in a blood vessel while also providing optional infusion and/or aspiration distal to the treatment area. In some embodiments, infusion, aspiration and guidewire passage occur through a common lumen. The thrombolytic agent, such as tPA, streptokinase, or urokinase, is directly released into the clot at the point where the agitator is engaging the clot. In this way, the thrombolytic activity of the agent is enhanced and the dissolution of the clot is improved.Type: GrantFiled: June 15, 2010Date of Patent: August 14, 2012Assignee: Tyco Healthcare Group LPInventors: Michael A. Evans, Denise Demarias, Dino De Cicco, Kelvin Ning, Alexander Khairkhahan, Tyler Jon Strang
-
Publication number: 20110046542Abstract: Clot disruption and dissolution are achieved using a catheter having the ability to infuse a thrombolytic agent, aspirate clot and fluid, and allow passage of a guidewire. Optionally, the catheter may also include a mechanical agitator for further disrupt clot in the presence of the thrombolytic agent. A flow resistor in the catheter provides for infusion and/or aspiration to be concentrated primarily at a clot treatment area in a blood vessel while also providing optional infusion and/or aspiration distal to the treatment area. In some embodiments, infusion, aspiration and guidewire passage occur through a common lumen. The thrombolytic agent, such as tPA, streptokinase, or urokinase, is directly released into the clot at the point where the agitator is engaging the clot. In this way, the thrombolytic activity of the agent is enhanced and the dissolution of the clot is improved.Type: ApplicationFiled: June 15, 2010Publication date: February 24, 2011Applicant: Bacchus Vascular Inc.Inventors: Michael A. Evans, Denise Demarias, Dino De Cicco, Kelvin Ning, Alexander Khairkhahan, Tyler Jon Strang
-
Patent number: 7763010Abstract: Clot disruption and dissolution are achieved using a catheter having the ability to infuse a thrombolytic agent, aspirate clot and fluid, and allow passage of a guidewire. Optionally, the catheter may also include a mechanical agitator for further disrupt clot in the presence of the thrombolytic agent. A flow resistor in the catheter provides for infusion and/or aspiration to be concentrated primarily at a clot treatment area in a blood vessel while also providing optional infusion and/or aspiration distal to the treatment area. In some embodiments, infusion, aspiration and guidewire passage occur through a common lumen. The thrombolytic agent, such as tPA, streptokinase, or urokinase, is directly released into the clot at the point where the agitator is engaging the clot. In this way, the thrombolytic activity of the agent is enhanced and the dissolution of the clot is improved.Type: GrantFiled: May 8, 2002Date of Patent: July 27, 2010Assignee: Bacchus Vascular inc.Inventors: Michael A. Evans, Denise Demarais, Dino De Cicco, Kelvin Ning, Alexander Khairkhahan, Tyler Jon Strang
-
Patent number: 6929633Abstract: Clot disruption and dissolution are achieved using a catheter having the ability to infuse a thrombolytic agent, agitate the clot and agent, and aspirate broken-up clot from the blood vessel. A flow resistor in the catheter provides for infusion and/or aspiration to be concentrated primarily at a clot treatment area in a blood vessel while also providing optional infusion and/or aspiration distal to the treatment area. In some embodiments, infusion, aspiration and guidewire passage occur through a common lumen. The thrombolytic agent, such as tPA, streptokinase, or urokinase, is directly released into the clot at the point where the agitator is engaging the clot. In this way, the thrombolytic activity of the agent is enhanced and the dissolution of the clot is improved.Type: GrantFiled: October 21, 2002Date of Patent: August 16, 2005Assignee: Bacchus Vascular, Inc.Inventors: Michael A. Evans, Denise Demarais, Dino De Cicco, Kelvin Ning, Alexander Khairkhahan, Tyler Jon Strang, Jody Maria Cimbalo, Stephen Leeflang
-
Publication number: 20030139751Abstract: Clot disruption and dissolution are achieved using a catheter having the ability to infuse a thrombolytic agent, agitate the clot and agent, and aspirate broken-up clot from the blood vessel. A flow resistor in the catheter provides for infusion and/or aspiration to be concentrated primarily at a clot treatment area in a blood vessel while also providing optional infusion and/or aspiration distal to the treatment area. In some embodiments, infusion, aspiration and guidewire passage occur through a common lumen. The thrombolytic agent, such as tPA, streptokinase, or urokinase, is directly released into the clot at the point where the agitator is engaging the clot. In this way, the thrombolytic activity of the agent is enhanced and the dissolution of the clot is improved.Type: ApplicationFiled: October 21, 2002Publication date: July 24, 2003Applicant: BACCHUS VASCULAR INC.Inventors: Michael A. Evans, Denise Demarais, Dino De Cicco, Kelvin Ning, Alexander Khairkhahan, Tyler Jon Strang, Jody Maria Cimbalo, Stephen Leeflang
-
Publication number: 20020188276Abstract: Clot disruption and dissolution are achieved using a catheter having the ability to infuse a thrombolytic agent, aspirate clot and fluid, and allow passage of a guidewire. Optionally, the catheter may also include a mechanical agitator for further disrupt clot in the presence of the thrombolytic agent. A flow resistor in the catheter provides for infusion and/or aspiration to be concentrated primarily at a clot treatment area in a blood vessel while also providing optional infusion and/or aspiration distal to the treatment area. In some embodiments, infusion, aspiration and guidewire passage occur through a common lumen. The thrombolytic agent, such as tPA, streptokinase, or urokinase, is directly released into the clot at the point where the agitator is engaging the clot. In this way, the thrombolytic activity of the agent is enhanced and the dissolution of the clot is improved.Type: ApplicationFiled: May 8, 2002Publication date: December 12, 2002Applicant: BACCHUS VASCULAR, INC.Inventors: Michael A. Evans, Denise Demarais, Dino De Cicco, Kelvin Ning, Alexander Khairkhahan, Tyler Jon Strang